ES 
EN 
Breve descripción
The PODOMOUNT-Basket study is evaluating whether an investigational once daily oral medication called Apecotrep reduces the amount of protein in the urine in adult patients with Alport syndrome, secondary FSGS, membranous nephropathy (MN), and in both adults and adolescents with minimal change disease (MCD).
Médico del ensayo / Coordinador del estudio
Kenneth Toribio
Estimated Enrollment
132
Estimated End Date
2/9/2028
Trial is for people with
Alport syndrome, primary membranous nephropathy, primary minimal change disease, secondary FSGS, as well as FSGS of undetermined ...
Study Goal
To learn more about the safety of apecotrep and determine if it may help people with four rare kidney diseases—primary minimal change ...
What is involved for the patient?
You will receive either study drug (apecotrep) or placebo for 20 weeks. The randomization will be 2:1, meaning twice as many patients ...
About the drug or intervention
Apecotrep is a once daily non-immunosuppressant oral medication that is designed to protect podocytes, the cells which keep protein ...
